文献速递甲状腺疾病

肿瘤多灶性对甲状腺乳头状癌临床结局的预后价值

The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer.
PubMed 文献 · J Clin Endocrinol Metab · 2017-01-01

多中心研究纳入2638例甲状腺乳头状癌(PTC)患者,随访中位58个月,多灶性与单灶性复发率为19.8% vs 13.6%(P<0.001),多因素校正后风险比降至1.13(95%CI 0.93-1.37)无统计学意义;多灶性与死亡率无关,SEER数据库89680例验证结果一致。

要点

  • 多灶性PTC与单灶性复发率19.8% vs 13.6%(P<0.001),但多因素校正后HR 1.13(95%CI 0.93-1.37)无统计学意义。
  • 多灶性与PTC患者死亡无关,经典危险因素与复发或死亡仍显著相关。
  • 甲状腺内PTC患者中多灶性与单灶性复发率4.4% vs 4.2%(P=0.892),死亡率0.0% vs 0.3%(P=0.556)。

核心结论

  • 肿瘤多灶性对PTC临床结局无独立风险预后价值,不应不加区分地将其作为独立危险因素而导致过度治疗。

研究设计与样本

  • 多中心研究,纳入6个国家11个医学中心的2638例PTC患者(男623例、女2015例),中位年龄46(35-58)岁,中位随访58(26-107)个月。
  • 使用监测、流行病学和最终结果(SEER)数据库数据(89680例PTC患者)进行验证。

主要发现

  • 多灶性与单灶性PTC复发分别为1000例中198例(19.8%)与1624例中221例(13.6%)(P<0.001),风险比1.55(95%CI 1.28-1.88),多因素校正后为1.13(95%CI 0.93-1.37)无统计学意义。
  • 在经典型PTC、滤泡变异型PTC、高细胞型PTC和甲状腺乳头状微小癌中结果相似。
  • 上述PTC情形中多灶性与死亡率均无关,而经典危险因素与癌症复发或死亡呈强关联且多因素校正后仍显著。
  • 甲状腺内PTC患者1423例中,多灶性与单灶性复发分别为455例中20例(4.4%)与967例中41例(4.2%)(P=0.892),死亡率分别为455例中0例(0.0%)与967例中3例(0.3%)(P=0.556)。
  • SEER数据库89680例PTC患者中重复出上述结果。

临床怎么用

  • 原文结论认为,不应不加区分地将肿瘤多灶性作为PTC的独立危险因素而促使对患者过度治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Multifocality is often treated as a risk factor for papillary thyroid cancer (PTC), prompting aggressive treatments, but its prognostic value remains unestablished. OBJECTIVE: To investigate the role of tumor multifocality in clinical outcomes of PTC. METHODS: Multicenter study of the relationship between multifocality and clinical outcomes of PTC in 2638 patients (623 men and 2015 women) with median [interquartile range (IQR)] age of 46 (35 to 58) years and median (IQR) follow-up time of 58 (26 to 107) months at 11 medical centers in six countries. Surveillance, Epidemiology and End Results (SEER) data were used for validation. RESULTS: Disease recurrence in multifocal and unifocal PTC was 198 of 1000 (19.8%) and 221 of 1624 (13.6%) (P < 0.001), with a hazard ratio of 1.55 [95% confidence interval (CI), 1.28 to 1.88], which became insignificant at 1.13 (95% CI, 0.93 to 1.37) on multivariate adjustment. Similar results were obtained in PTC variants: conventional PTC, follicular-variant PTC, tall-cell PTC, and papillary thyroid microcarcinoma. There was no association between multifocality and mortality in any of these PTC settings, whereas there was a strong association between classic risk factors and cancer recurrence or mortality, which remained significant after multivariate adjustment. In 1423 patients with intrathyroidal PTC, disease recurrence was 20 of 455 (4.4%) and 41 of 967 (4.2%) (P = 0.892) and mortality was 0 of 455 (0.0%) and 3 of 967 (0.3%) (P = 0.556) in multifocal and unifocal PTC, respectively. The results were reproduced in 89,680 patients with PTC in the SEER database. CONCLUSIONS: Tumor multifocality has no independent risk prognostic value in clinical outcomes of PTC; its indiscriminate use as an independent risk factor, prompting overtreatments of patients, should be avoided.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Wang F, Yu X, Shen X, et al. The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer. J Clin Endocrinol Metab. 2017. PMID: 28582521. doi:10.1210/jc.2017-00277

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。